A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Feb 18, 2016

Keywords

ClinConnect Summary

This clinical trial is investigating a new test that helps doctors determine whether patients with stage III clear cell renal cell carcinoma (a type of kidney cancer) should receive additional targeted therapy after their surgery. The test looks at specific markers in the blood to classify patients into high-risk and low-risk groups for cancer recurrence. The main goal of the trial is to see how effective adjuvant targeted therapy is for those identified as high-risk compared to simply monitoring their health without immediate treatment.

To be eligible for this trial, participants must be adults aged 18 and older with a confirmed diagnosis of stage III clear cell renal cell carcinoma who have not received any cancer treatment before their surgery. Participants should also be in good health, as indicated by a specific health rating. Those with serious health issues or who are pregnant or breastfeeding cannot participate. If you join the trial, you will be randomly assigned to either receive the targeted therapy or just have regular check-ups, and the researchers will track your health outcomes over time to see how well you do.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The informed consent has been obtained from the patient.
• • With confirmed diagnosis of stage III clear cell renal cell carcinoma
• • With moderate/good ECOG health rating (PS): 0-1 score.
• • The patient receive no anti-cancer treatment before primary surgery.
• • The patient receive radical operation for renal cancer with negative margin.
• Exclusion Criteria:
• • With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
• • With bad compliance or contraindication to enrollment.
• • Pregnant woman or lactating woman.
• • With contraindication to receive adjuvant targeted therapy.